Call for papers: Special collection honoring Dr. Mikhail (Misha) Blagosklonny
Business Announcement
The Icahn School of Medicine at Mount Sinai has launched the AI Small Molecule Drug Discovery Center, a bold endeavor that harnesses artificial intelligence (AI) to revolutionize drug development. The new Center will integrate AI with traditional drug discovery methods to identify and design new small-molecule therapeutics with unprecedented speed and precision. Unlike conventional drug discovery, which can take years and cost billions, AI-driven approaches enable researchers to rapidly navigate a vast chemical landscape, including natural products, to pinpoint promising drug candidates. By leveraging Mount Sinai’s world-leading expertise in machine learning, chemical biology, and biomedical data science, the Center aims to bring innovative treatments to patients faster—particularly for diseases with urgent unmet needs, including cancer, metabolic disorders, and neurodegenerative diseases.
Terrestrial carbon cycle dynamics remain one of the greatest sources of uncertainty in climate projections, with diverging estimates of ecosystem carbon uptake, affecting the accuracy of Earth system models.
To address these challenges, CONCERTO (Improved CarbOn cycle represeNtation through multi-sCale models and Earth obseRvation for Terrestrial ecOsystems), was launched in January 2025.
Europe’s approximately 80,000 sewage treatment plants offer considerable potential for an innovative, carbon-neutral process for the production of the universal chemical methanol.. ICODOS, a start-up founded at the Karlsruhe Institute of Technology (KIT), and its partners have built an innovative facility at Mannheim’s sewage treatment plant. The facility purifies the biogas produced by the plant and uses green hydrogen to convert it into carbon-neutral fuel for ships. They opened the facility today, March 24, 2025.
When choosing an embryo for implantation during in vitro fertilization (IVF), would you consider its chances of developing a health condition? What about traits like creativity, intelligence, or physical fitness? Tinker Tots is an interactive research project designed to explore how people make these difficult choices. By taking part, you help researchers understand how different genetic possibilities influence decision-making—while also gaining insight into your own and other people’s values.
The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS). IPWSO hopes the US FDA approval is the first step towards ensuring that all individuals with PWS who need access to these novel therapeutics will soon find them available, and accessible, in their own countries. As part of its global mission, IPWSO continues to advocate for equitable access to life-changing treatments, working with regulatory agencies, policymakers, and the rare disease community to remove barriers and accelerate availability worldwide.